Ranbaxy Also Could Face Probe By Indian Authorities
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories not only faces an investigation in the U.S., it also could become the subject of a probe at home in India. Indian authorities have raised questions about whether Ranbaxy's stockholders were informed about U.S. FDA allegations that the firm marketed adulterated generics. Indian authorities are expected to review the same documents requested by U.S. authorities, to see if the company adequately informed shareholders of the financial risks involved in the investigation. (Click here for more